Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Kirill Kosilov, Irina Kuzina, Vladimir Kuznetsov, Yuliya Gainullina, Liliya Kosilova, Alexandra Prokofyeva & Sergey Loparev. (2018) Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage. The Aging Male 21:2, pages 121-129.
Read now
Read now
Javier C. Angulo. (2015) Combination therapy with tamsulosin and solifenacin for male lower urinary tract symptoms with predominant filling symptoms: a new approach to an old problem. Current Medical Research and Opinion 31:11, pages 1963-1965.
Read now
Read now
Articles from other publishers (19)
Muhammad A. PALINRUNGI, Haerani RASYID, Prihantono PRIHANTONO, Muhammad H. CANGARA, Agussalim BUKHARI, Harrina E. RAHARDJO, Syakri SYAHRIR & Andi A. ZAINUDDIN. (2023) Double-J stent-related lower urinary tract symptoms: a prospective randomized trial of mirabegron, solifenacin, tamsulosin, and tadalafil and their combinations. Gazzetta Medica Italiana Archivio per le Scienze Mediche 182:10.
Crossref
Crossref
Martin C. Michel, Linda Cardozo, Christopher J. Chermansky, Francisco Cruz, Yasuhiko Igawa, Kyu-Sung Lee, Arun Sahai, Alan J. Wein & Karl-Erik Andersson. (2023) Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders. Pharmacological Reviews 75:4, pages 554-674.
Crossref
Crossref
Jozef Marenčák. (2023) What is new in the pharmacotherapy of benign prostatic hyperplasia. Klinická farmakologie a farmacie 37:1, pages 10-18.
Crossref
Crossref
Zhinan Fan, Hongjin Shi, Jinsong Zhang, Haifeng Wang & Jiansong Wang. (2022) Comparative Efficacy of Different Drugs for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Bayesian Network Meta-Analysis. Frontiers in Pharmacology 13.
Crossref
Crossref
Aleš Horák. (2021) The actual pharmacotherapy benign hyperplasia according to EAU Guidelines. Urologie pro praxi 22:3, pages 125-132.
Crossref
Crossref
Keisuke Ishikawa, Akira Tsujimura, Miho Miyoshi, Yuto Miyoshi, Taiki Ogasa, Ippei Hiramatsu, Yuka Uesaka, Taiji Nozaki, Masato Shirai, Isao Mitsuhashi, Sosuke Sugimura, Taiki Mizuno, Kensho Noto, Yasuhiro Shigeta, Shinichi Honda, Shinji Iwata & Shigeo Horie. (2021) Efficacy and Safety of Vibegron Add-on Therapy in Men With Persistent Storage Symptoms After Receiving Alpha 1-Blocker or Phosphodiesterase 5 Inhibitor: A Preliminary Study. Urology 153, pages 256-263.
Crossref
Crossref
Emanuele Rubilotta. 2021. Non-Neurogenic Bladder Dysfunctions. Non-Neurogenic Bladder Dysfunctions
67
85
.
Tong Cai, Ning Wang, Liye Liang, Zhongbao Zhou, Yong Zhang & Yuanshan Cui. (2020) Meta-Analysis of the Efficacy and Safety of Imidafenacin for Overactive Bladder Induced by Benign Prostatic Hyperplasia in Men Receiving Alpha-Blocker Therapy. International Neurourology Journal 24:4, pages 365-374.
Crossref
Crossref
Yuxuan Song, Guangyuan Chen, Peng Huang, Cong Hu & Xiaoqiang Liu. (2020) Effects of Tamsulosin Combined With Solifenacin on Lower Urinary Tract Symptoms: Evidence From a Systematic Review, Meta-Analysis, and Trial Sequential Analysis of Randomized Controlled Trials. Frontiers in Pharmacology 11.
Crossref
Crossref
Zhao-Jun Yu, Hai-Lan Yan, Fang-Hua Xu, Hai-Chao Chao, Lei-Hong Deng, Xiang-Da Xu, Jian-Biao Huang & Tao Zeng. (2020) Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia. Frontiers in Pharmacology 11.
Crossref
Crossref
Kirill Kosilov, Irina Kuzina, Vladimir Kuznetsov, Liliya Kosilova, Marina Ivanovskaya & Ekaterina Kosilova. (2020) The Analysis of the Effects of Executive Functions, Working Memory and Other Factors on Medication Adherence in Elderly Men with Benign Prostatic Hyperplasia and Overactive Bladder Symptoms. Current Aging Science 13:1, pages 72-80.
Crossref
Crossref
Shunye Su, Jinlei Lin, Liqin Liang, Ludong Liu, Zhipeng Chen & Yuan Gao. (2020) The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy. Medicine 99:4, pages e18802.
Crossref
Crossref
Shinji Urakami, Kohei Ogawa, Suguru Oka, Kiichi Hagiwara, Shoichi Nagamoto, Haruki Anjiki, Michikata Hayashida, Akihiro Yano, Kazushige Sakaguchi, Kazuhiro Kurosawa & Toshikazu Okaneya. (2018)
Effect of tadalafil add‐on therapy in patients with persistant storage symptoms refractory to α
1
‐adrenoceptor antagonist monotherapy for benign prostatic hyperplasia: A randomized pilot trial comparing tadalafil and solifenacin
. LUTS: Lower Urinary Tract Symptoms 11:3, pages 109-114.
Crossref
Crossref
Alex Gomelsky, Emily F. Kelly & Rebecca Budish. 2019. Contemporary Pharmacotherapy of Overactive Bladder. Contemporary Pharmacotherapy of Overactive Bladder
245
265
.
Alison Sih, Meredith Angel & Michel Pontari. (2018) Prevalence of Urgency in Patients with LUTS Due to BPE. Current Bladder Dysfunction Reports 13:1, pages 8-12.
Crossref
Crossref
Antoni Sicras-Mainar, Ruth Navarro-Artieda, Ana Mª. Mora & Marta Hernández. (2017) Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia. BMC Urology 17:1.
Crossref
Crossref
Yukio Homma, Momokazu Gotoh, Akihiro Kawauchi, Yoshiyuki Kojima, Naoya Masumori, Atsushi Nagai, Tadanori Saitoh, Hideki Sakai, Satoru Takahashi, Osamu Ukimura, Tomonori Yamanishi, Osamu Yokoyama, Masaki Yoshida & Kenji Maeda. (2017) Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. International Journal of Urology 24:10, pages 716-729.
Crossref
Crossref
Seok Cho, Soon-Sun Kwon, Kwang Woo Lee, Tag Keun Yoo, Dong Gil Shin, Soo Woong Kim, Jae Hyun Bae, Hoon Choi & Young Ho Kim. (2017) A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. International Journal of Clinical Practice 71:5, pages e12938.
Crossref
Crossref
Matthew C. Moss, Tameem Rezan, Umar R. Karaman & Alex Gomelsky. (2017) Treatment of Concomitant OAB and BPH. Current Urology Reports 18:1.
Crossref
Crossref